CHARLOTTE, N.C., Feb. 17, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the Company has completed a second analysis of data from the open-label titration portion of its Phase III Study 302 which demonstrated patients treated with Droxidopa, a synthetic precursor to norepinephrine, showed a similarly robust reduction in the severity of symptoms associated with neurogenic orthostatic hypotension (NOH) and a improvement standing systolic blood pressure as reported in November 2008.
